Trilogie was founded to solve a critical gap in ubiquitin-proteasome system (UPS) research: the paucity of high-specific-activity, biologically validated reagents and services that reflect the true complexity of UPS biology. Whether you’re mapping E3-substrate interactions, screening DUB inhibitors, or engineering protein degraders, we believe experimental outcomes depend on functional precision, starting with the reagents themselves. Our focus: Expression scouting and optimization for ligases, substrates, adaptors, and complex UPS proteins Mechanism-aligned assay development for ubiquitylation cascades and degrader mode-of-action studies Growing catalog of ready-to-use UPS tools designed to support academic and drug discovery researchers with reagents that perform reliably
| Website | https://trilogiebio.com/ |
| Employees | 8 (6 on RocketReach) |
| Founded | 2024 |
| Industry | Biotechnology Research |
Looking for a particular Trilogie Bioscience employee's phone or email?
Bradley Brasher is the Chief Science Officer of Trilogie Bioscience.
6 people are employed at Trilogie Bioscience.